This initial, proof of concept study will focus on identifying significant differences in response to the Ebolavirus Zaire vaccine (ChAd3-EBO-Z) when administered with placebo, MVA-BN(R)-Filo, or ChAd3-EBO-Z boosters after 8 days. All 60 participants will receive the ChAd3-EBO-Z vaccine and then randomized into each booster group (20 receiving each type of booster). Subjects will be followed-up for 6 months to monitor for safety outcomes and efficacy measures. There is no formal hypothesis for this study. The primary objective of this study is to assess the safety and reactogenicity of study products by study group when administered IM to healthy adults.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Clinical Safety Laboratory Adverse Events
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants Reporting Serious Adverse Events (SAEs)
Timeframe: Day 1 to Day 182
Number of Participants Reporting Solicited Local Reactogenicity
Timeframe: Day 1 to Day 8 Post First Vaccination
Number of Participants Reporting Solicited Local Reactogenicity
Timeframe: Day 1 to Day 8 Post Second Vaccination
Number of Participants Reporting Solicited Local Reactogenicity
Timeframe: Day 1 to Day 15
Number of Participants Reporting Solicited Systemic Reactogenicity
Timeframe: Day 1 to Day 8 Post First Vaccination
Number of Participants Reporting Solicited Systemic Reactogenicity
Timeframe: Day 1 to Day 8 Post Second Vaccination
Number of Participants Reporting Solicited Systemic Reactogenicity
Timeframe: Day 1 to Day 15
Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)
Timeframe: Day 1 to Day 182
Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination
Number of Participants by Severity of Solicited Local Reactogenicity
Timeframe: Day 1 to Day 8 Post First Vaccination
Number of Participants by Severity of Solicited Local Reactogenicity
Timeframe: Day 1 to Day 8 Post Second Vaccination
Number of Participants by Severity of Solicited Local Reactogenicity
Timeframe: Day 1 to Day 15
Number of Participants by Severity of Solicited Systemic Reactogenicity
Timeframe: Day 1 to Day 8 Post First Vaccination
Number of Participants by Severity of Solicited Systemic Reactogenicity
Timeframe: Day 1 to Day 8 Post Second Vaccination
Number of Participants by Severity of Solicited Systemic Reactogenicity
Timeframe: Day 1 to Day 15
Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)
Timeframe: Day 1 to approximately 28 Days Post Second Vaccination